Industry Veterans Dr. Ashok Srivastava and Elias Tharakan Launch AyurDatta to Bridge the Gap Between Clinical Science and AI-Powered Execution for Biopharma Innovators

PRINCETON, NJ, October 12, 2025 - Today marks the official launch of AyurDatta, a new global, full-service provider designed to address a critical gap in the drug development industry: the disconnect between brilliant clinical science and the complex operational execution required for regulatory success. Founded by world-renowned oncologist Dr. Ashok Srivastava and visionary technology executive Elias Tharakan, AyurDatta offers a new, integrated partnership model for biopharma innovators, particularly those in the oncology, hematology, and rare disease sectors.

AyurDatta is founded on the principle that the most promising therapies deserve the most robust and intelligent pathway to patients. The company will provide a comprehensive suite of services, including end-to-end clinical development, pharmacovigilance, and global regulatory affairs, all underpinned by a proprietary, AI-powered technology framework.

The company's unique value proposition lies in the fusion of its founders' unparalleled expertise. Dr. Srivastava brings over 17 years of "hands-on" clinical and regulatory leadership, having successfully guided over 130 global oncology trials and contributed to numerous BLA and NDA approvals for advanced therapies, including CAR-T. Elias Tharakan provides the proven operational and technological engine as the architect of the industry's first unified eClinical SaaS platform, which has powered over 1,000 studies and supported dozens of drug approvals.

"Throughout my career, I have seen the immense promise of new cancer therapies and the daunting challenges that stand in the way of getting them to patients," said Dr. Ashok Srivastava, Co-Founder and Chief Medical Officer of AyurDatta. "This mission is deeply personal for both me and Elias. We created AyurDatta to be the partner we believe the industry needs-one that combines deep, physician-led scientific wisdom with the speed and precision that only advanced technology can provide. We are here to clear the path for innovators."

AyurDatta's service model is designed to function as a seamless extension of its clients' teams, providing the strategic guidance and operational horsepower needed to navigate complex trials, mitigate risks, and deliver high-quality, submission-ready data.

"For too long, the clinical and technological aspects of drug development have operated in separate worlds. This creates friction, delays, and inefficiencies that neither patients nor sponsors can afford," said Elias Tharakan, Co-Founder and Chief Executive Officer of AyurDatta. "At AyurDatta, we have eliminated that friction. By integrating my experience in building compliant, AI-powered operational systems with Ashok's world-class clinical expertise, we offer a single, accountable team focused on one thing: getting results. We are built to execute with the urgency and excellence that modern medicine demands."

About the Founders:

Dr. Ashok Srivastava, MD, Ph.D., MBA, is a board-certified oncologist and a global leader in clinical development. His distinguished career includes leadership roles at Pfizer Oncology, Daiichi Sankyo, and Autolus. He has been instrumental in the filing of 27 INDs, 9 NDAs, and 3 BLAs, and played a key role in the approval of the CAR-T therapy AUCATZYL® (Obe-cel). He received his clinical oncology and hematology training at the Dana-Farber Cancer Institute at Harvard University and the National Cancer Institute (NCI), NIH.

Elias Tharakan is a visionary technology and operations executive with a 20-year track record in clinical research technology. He architected and led the development of the industry's first unified eClinical SaaS platform, which powered over 1,000 studies and was instrumental in the approval of numerous blockbuster drugs. He pioneered the "FAST" implementation methodology, which accelerated trial timelines by over 70%, and developed a proprietary "Compliant AI" framework to ensure technology meets stringent global regulatory requirements.

5 Independence Way, Suite 300
Princeton, NJ 08540
United States

About AyurDatta:

AyurDatta is a global, full-service provider dedicated to accelerating the path to approval for biopharma innovators. Founded by leaders in clinical oncology and AI-powered technology, the company offers a unique, integrated service model that fuses deep medical and regulatory wisdom with flawless operational execution. Specializing in oncology, hematology, and rare diseases, AyurDatta functions as a true partner to its clients, providing a clear, data-driven, and accelerated pathway to bring life-changing therapies to patients.

For more information, visit www.ayurdatta.com.

This release was published on openPR.